Benzamide, 4-[[[4-(1,1-dimethylethyl)phenyl]methyl][2-[[(4-fluorophenyl)sulfonyl][(2,3,4,5,6-pentafluorophenyl)methyl]amino]acetyl]amino]-N-hydroxy-;AES135,HDAC,HDAC3,HDAC11,pancreatic,HDAC6,anti-tumor,Inhibitor,AES 135,Histone deacetylases,inhibit,AES-135;AES-135, 10 mM in DMSO
AES-135 is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor with anti-tumor activity, specifically inhibiting HDAC3, HDAC6, HDAC8, and HDAC11 (IC50 = 190–1100 nM). It demonstrates potent in vitro anti-proliferative effects against various cancer cell lines, including pancreatic, leukemia, breast, and prostate cancer cells. In vivo, AES-135 significantly prolongs survival in orthotopic pancreatic cancer mouse models (e.g., C57Bl/6 mice implanted with KPC2 cells) when administered intraperitoneally at 50 mg/kg, five days per week for one month. It exhibits favorable pharmacokinetics in mice, achieving micromolar blood concentrations with a half-life of 5.0 hours, supporting its potential as a therapeutic agent for cancer treatment.